Efficacy of the Buzzy® Device on the Prevention of Health Care Induced Pediatric Pain in a Vaccination Center

Vaccination Clinical Trial

— DOLVAX  

Official title:

Efficacy of a Cold, Vibration, and Distraction Based Medical Device on the Prevention of Health Care Induced Pediatric Pain: a Comparative, Controlled, Randomized and Multicentric Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03220555
• Other study ID #: RC17_0035
• Status: Completed
• Phase: N/A
• Start date: October 4, 2017
• Est. completion date: September 14, 2018

Study information

• Verified date: September 2021
• Source: Nantes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In vaccination centers, venipunctures and vaccinations are sources of pain and anxiety in pediatric patients. Prior painful experiences can reduce the acceptance of later health care, hence making it more difficult for both patients and nurses. The topical anesthetic cream (lidocaine, prilocaine) and the non-pharmacological (distraction and relaxation) interventions which are usually used for prevention of procedural pain impose certain constraints on families and on vaccination centers. A distraction and local anesthesia (cold and vibration) based medical device (Buzzy®) could overcome these constraints and could be an interesting alternative for healthcare management in vaccination centers and, in a broader perspective, in other medical services. Research on this device has been scarce to date. Three of them have shown an efficacy of Buzzy® in comparison to the absence of prevention of vaccination and venipuncture induced pain. An ongoing study will assess the Buzzy® device in comparison to a topical anesthetic cream, but will be set in an emergency department context. To date, no study has compared Buzzy® to topical anesthetic cream on healthy children in a vaccination center. The research team has formulated the following hypothesis: the Buzzy® device will allow to get a not lower or an equivalent level of pain compared to the level of pain obtained with the usual topical anesthetic cream. The aim of this study is to evaluate the efficacy of the device Buzzy® on vaccination and venipuncture induced pain in a vaccination center.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 220
• Est. completion date: September 14, 2018
• Est. primary completion date: September 14, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years to 15 Years

Eligibility

Inclusion Criteria:

Any child who:

• requires a venipuncture or a vaccination in a vaccination center
• is 4 to 15 years old
• is affiliated to the public social security
• speaks French or is assisted by an translator in the language of the child
• has given his oral consent and whose parents have given it Exclusion Criteria:

Any child who:

• suffers from sickle cell anemia
• has a contraindication to use lidocaine patch
• requires a Bacille de Calmette et Guérin (BCG) vaccine or tuberculin test
• takes part in another research
• has already participated to this study for another nursing care.
• refused to participate or whose parents refused
• has neurological or psychiatric disorders
• has a nerve damage or an abrasion of the skin in terms of puncture or injection area.
• under trusteeship or guardianship (unaccompanied foreign minors).

Related Conditions & MeSH terms

• Intravenous Injections
• Vaccination

Intervention

Device:
• Buzzy® device
Just before the vaccination or venipuncture the device will be applied on the selected site during 30 seconds and then it will be moved 5 cm above the selected site to make the injection or the puncture. The child will choose if he wants to use the cooling system.

Drug:
• EMLAPATCH (lidocaine, prilocaine)
The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.

Locations

Country	Name	City	State
France	La Roche sur Yon University Hospital	La Roche-sur-Yon
France	Le Mans University Hospital	Le Mans
France	Nantes University Hospital	Nantes

Sponsors (1)

Lead Sponsor	Collaborator
Nantes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Faces Pain Scale revised (FPS-r) for children	Pain will be assessed by child using the FPS-r. FPS-r is a tool which has been validated and has been shown to be reliable in intercultural children and adolescents population (4 to 17 years).	Day 0
Secondary	Faces Pain Scale revised (FPS-r) for parents	Pain will be assessed by a parent using the FPS-r. FPS-r is a tool which has been validated and has been shown to be reliable in intercultural children and adolescents population (4 to 17 years).	Day 0
Secondary	Differential cost of the two strategies compared to the differential pain	Differential cost of the two strategies compared to the differential pain, self-reported by children with the FPS-r. Cost assessment of the two strategies will be made by a micro-costing analysis. The parameters analyzed will be : the strategy used (Buzzy® device or EMLAPATCH), the nurses' time and the time spent by child in the vaccination center. This parameters will be aggregated and will be presented in the form of a cost-effectiveness differential ratio and acceptability curves.	Day 0